Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHOLESTYRAMINE vs AMINO ACIDS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cholestyramine is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum low-density lipoprotein (LDL) cholesterol levels.
Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.
Primary hypercholesterolemia (Type IIa hyperlipoproteinemia),Pruritus associated with partial biliary obstruction and primary biliary cirrhosis,Pseudomembranous colitis (Clostridioides difficile infection)-associated diarrhea (adjunctive),Diarrhea associated with bile acid malabsorption,Eczema (off-label),Hyperoxaluria (off-label)
Total parenteral nutrition (TPN) for patients unable to ingest or absorb adequate nutrients,Supplementation in metabolic disorders (e.g., urea cycle disorders, maple syrup urine disease),Treatment of negative nitrogen balance due to trauma, burns, or surgery
4 g orally once or twice daily, titrated up to 24 g/day divided into 2-6 doses; usual maintenance dose 8-16 g/day
1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.
Not applicable; cholestyramine is not absorbed and does not have a systemic half-life. Its clinical effect is related to gastrointestinal transit time.
Variable; endogenous amino acids: 10–30 min for clearance from plasma; administered doses: distribution half-life ~5–10 min, terminal elimination half-life ~15–30 min, reflecting rapid metabolic utilization and renal reabsorption.
Cholestyramine is not absorbed systemically; it acts locally in the gastrointestinal tract and is excreted unchanged in feces.
Amino acids are metabolized primarily in the liver via transamination, deamination, and urea cycle. Specific pathways exist for each amino acid; excess nitrogen is converted to urea.
Cholestyramine is not absorbed systemically; it remains in the gastrointestinal tract and is excreted unchanged in feces. No renal or biliary elimination occurs.
Renal: >95% as amino acids and metabolites, primarily reabsorbed; <5% unchanged. Fecal/biliary: negligible (<1%).
Not applicable; cholestyramine is not absorbed and does not bind to plasma proteins.
Minimal for most amino acids (<10%); albumin and globulins bind tryptophan and aromatic amino acids (~80–90% for tryptophan).
Not applicable; due to lack of systemic absorption, Vd is essentially zero.
0.4–0.6 L/kg (total body water); reflects equilibration with intracellular and extracellular fluid compartments.
Oral: <0.1% (negligible systemic absorption); cholestyramine acts locally in the gastrointestinal tract.
Oral: ~90–100% (active transport across intestinal mucosa); IV: 100%.
No dosage adjustment required for renal impairment; caution in patients with severe renal disease due to risk of hyperchloremic metabolic acidosis
For GFR <30 m L/min: reduce dose to 0.5-1 g/kg/day; monitor serum amino acids and nitrogen balance.
Use with caution in cirrhosis or cholestatic disorders; no specific Child-Pugh guidelines; monitor for increased bleeding risk due to vitamin K malabsorption
Child-Pugh B or C: avoid standard formulations; use branched-chain amino acid (BCAA)-enriched solutions at 0.8-1.2 g/kg/day.
Initial 240 mg/kg/day (approximately 0.625 g/kg/day) divided into 2-3 doses, titrated based on response; maximum 8 g/day
0.5-2 g/kg/day IV; titrate based on age, growth, and metabolic needs.
Start at low end of dosing range (4 g/day) due to increased risk of constipation and fecal impaction; monitor for electrolyte disturbances and drug interactions
Initiate at 0.8 g/kg/day IV, adjust based on renal function and nitrogen balance; monitor for fluid overload.
No FDA black box warning.
Patients receiving amino acid infusions should be monitored for metabolic acidosis, hyperammonemia, and renal function impairment. Solutions with electrolytes should not be used in patients with severe electrolyte imbalances.
May reduce absorption of fat-soluble vitamins (A, D, E, K) and folic acid; supplementation may be required.,May impair absorption of other medications (e.g., digoxin, warfarin, thyroid hormones); administer at least 4-6 hours before or after cholestyramine.,May cause hyperchloremic metabolic acidosis, especially in pediatric patients.,May exacerbate hemorrhoids due to constipation.,Use with caution in patients with phenylketonuria (contains aspartame in some formulations).
Use with caution in patients with renal impairment, hepatic failure, heart failure, or metabolic acidosis. Monitor serum electrolytes, blood urea nitrogen, and ammonia levels. Avoid rapid infusion to prevent hyperosmolarity and venous thrombosis.
Complete biliary obstruction (unable to excrete bile into intestine),Hypersensitivity to cholestyramine or any component,Phenylketonuria (if product contains aspartame)
Hypersensitivity to any component, inborn errors of amino acid metabolism (e.g., phenylketonuria) without specific formula, severe hyperammonemia, anuria, or metabolic acidosis.
Cholestyramine may interfere with absorption of fat-soluble vitamins (A, D, E, K). Long-term use may require supplementation. Administer with meals to bind bile acids. High-fiber foods may help counteract constipation. Avoid taking cholestyramine close to other medications or foods that require optimal absorption.
No significant food interactions; however, enteral nutrition should be managed to avoid excessive protein intake. Patients with phenylketonuria must avoid phenylalanine-containing amino acid solutions.
Cholestyramine is not absorbed systemically; therefore, direct fetal exposure is negligible. No teratogenic effects have been reported in animal studies or human case reports. However, due to potential maternal fat-soluble vitamin deficiency (A, D, E, K) caused by the drug, indirect fetal risk exists, especially in the first trimester for neural tube defects (vitamin A) and second/third trimester for coagulation (vitamin K). Use only if clearly needed and monitor maternal vitamin levels.
Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimester-specific human data; animal studies show no teratogenicity at standard doses.
Cholestyramine is not excreted into breast milk due to negligible systemic absorption. It is considered compatible with breastfeeding, as no adverse effects on the nursing infant have been reported. M/P ratio is not applicable. Monitor infant for signs of vitamin deficiency if mother uses high doses long-term.
Amino acids are normal constituents of breast milk; supplementation likely results in increased maternal levels but endogenous secretion maintains relatively constant milk levels. M/P ratio not established; generally considered compatible with breastfeeding at recommended doses.
No dose adjustment is needed for pregnancy because cholestyramine is not absorbed systemically. However, consider increasing the dose if concurrent vitamin supplementation is used, as cholestyramine may bind and reduce absorption of fat-soluble vitamins. Administer vitamins at least 1 hour before or 4-6 hours after cholestyramine. Monitor for adequate therapeutic effect; dose may be adjusted based on clinical response (e.g., pruritus or diarrhea control).
No specific dose adjustments required for enteral amino acids. For parenteral nutrition, consider increased requirements in third trimester (protein needs up to 1.5 g/kg/day). Adjust based on maternal weight gain, renal function, and metabolic monitoring.
Cholestyramine is a bile acid sequestrant used to lower LDL cholesterol by binding bile acids in the intestine, increasing their fecal excretion, and upregulating hepatic LDL receptors. It is also used for pruritus associated with cholestasis and for diarrhea due to bile acid malabsorption. Administer other medications at least 1 hour before or 4-6 hours after cholestyramine, as it can impair absorption of many drugs (e.g., warfarin, digoxin, thyroid hormones). Monitor for constipation, which is common and can be severe; increase fiber and fluid intake. Cholestyramine can cause hypertriglyceridemia; check triglycerides before and during therapy. It may reduce absorption of fat-soluble vitamins (A, D, E, K); consider supplementation with long-term use.
Amino acid infusions should be administered via central line if osmolarity > 900 m Osm/L to prevent thrombophlebitis. Monitor serum ammonia and BUN in patients with hepatic or renal impairment. Use with caution in patients with inborn errors of amino acid metabolism.
Take this medication exactly as prescribed, usually 2-4 times daily with meals or at bedtime.,Mix the powder with at least 4-8 ounces of water, fruit juice, or non-carbonated beverage; stir well and drink immediately. Do not swallow dry powder.,Do not take other medications or supplements within 1 hour before or 4-6 hours after taking cholestyramine, as it can prevent their absorption.,Increase fluid and dietary fiber intake to help prevent constipation. Notify your doctor if constipation becomes severe or if you have stomach pain.,Inform your doctor if you develop unusual bleeding or bruising, which may indicate vitamin K deficiency.,Cholestyramine may increase blood triglyceride levels; your doctor will monitor your blood lipid profile.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss risks and benefits with your doctor.,Store at room temperature, away from moisture and heat.
This medication provides essential building blocks for protein synthesis.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing.,Inform your doctor if you have liver or kidney disease.,Do not take other protein supplements unless directed by your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHOLESTYRAMINE vs AMINO ACIDS, answered by our medical review team.
CHOLESTYRAMINE is a Bile Acid Sequestrant that works by Cholestyramine is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum low-density lipoprotein (LDL) cholesterol levels.. AMINO ACIDS is a Parenteral Nutrition Solution that works by Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHOLESTYRAMINE and AMINO ACIDS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHOLESTYRAMINE is: 4 g orally once or twice daily, titrated up to 24 g/day divided into 2-6 doses; usual maintenance dose 8-16 g/day. The standard adult dose of AMINO ACIDS is: 1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHOLESTYRAMINE and AMINO ACIDS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHOLESTYRAMINE is classified as Category C. Cholestyramine is not absorbed systemically; therefore, direct fetal exposure is negligible. No teratogenic effects have been reported in animal studies or human case reports. Howe. AMINO ACIDS is classified as Category C. Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.